All In Vivo Testing articles
-
NewsCopper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study
A copper-delivering compound has demonstrated the ability to restore blood-brain barrier clearance mechanisms, reducing amyloid-beta accumulation by 42 percent and improving spatial learning by 44 percent in Alzheimer’s disease models, according to research published in ACS Chemical Neuroscience.
-
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a potential new approach for treating cardiovascular disease.
-
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
-
NewsHow researchers are recreating the human heart in the lab
Many promising therapies fail because preclinical models do not fully capture the complexity of the human heart. A new review explores how 3D cardiac constructs could improve disease modelling, drug screening and safety assessment.
-
NewsCardiac organoids repair heart attack damage in preclinical study
Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into damaged heart tissue in porcine models of myocardial infarction, improving cardiac function and reducing scar formation without triggering arrhythmias.
-
NewsISSCR consortium submits recommendations on NAMs to FDA
The ISSCR Consortium on Advanced Stem Cell-Based Models is calling for greater flexibilty from the FDA to accomodate rapidly changing technologies like stem cell-derived systems, organoids and computational approaches.
-
NewsGut-targeted drug proves effective against polycystic ovary syndrome in mice
Fudan University researchers report that fexaramine, an intestine-specific farnesoid X receptor agonist, improved metabolic and reproductive parameters in mouse models of polycystic ovary syndrome, supporting the gut–ovary axis hypothesis.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsAI system reduces animal testing in drug discovery by 50 percent
German researchers have developed genESOM, a generative AI system that could reduce animal numbers in preclinical drug testing by 30 to 50 percent.
-
NewsTwo antimicrobials show efficacy against drug-resistant pneumonia pathogen
A preclinical study from Osaka Metropolitan University demonstrates that levofloxacin and cefiderocol both show therapeutic potential against severe hemorrhagic pneumonia caused by the multidrug-resistant pathogen Stenotrophomonas maltophilia.
-
NewsBispecific antibody targets Wnt co-receptors for diabetic macular oedema treatment
Preclinical data presented at ARVO 2026 demonstrate therapeutic potential of targeting Gpr124 and Lrp6 Wnt co-receptors to restore blood-retina barrier integrity in diabetic macular oedema and wet age-related macular degeneration, with trispecific candidate NVQ501 advancing towards IND-enabling studies.
-
NewsNew dual-action drug candidate extends survival in pancreatic cancer models
Researchers have developed a dual-mechanism compound that significantly extended survival in preclinical pancreatic cancer models by simultaneously activating immune responses and blocking suppressive pathways.
-
NewsHybrid molecule shows enhanced metabolic effects in obesity study
A novel hybrid molecule combining incretin therapy with targeted intracellular delivery of a PPAR agonist has demonstrated strong weight loss and glucose control compared to existing GLP-1/GIP therapies in preclinical studies.
-
ArticleWhy lower organisms matter for neurodegeneration drug discovery
In the wake of recent government policy aimed at actively replacing animal models in drug discovery, we consider a possible solution to the translational shortfalls of current cellular methodologies for neurodegenerative disease.
-
NewsNew osteoarthritis therapy targeting joint repair advances following preclinical success
A Duke Health-led consortium has achieved key preclinical milestones in developing regenerative therapies that target cartilage and bone damage in osteoarthritis, potentially offering an alternative to symptom management and joint replacement surgery.
-
NewsSmall molecule SK-129 targets protein aggregation in Parkinson’s disease
International researchers have identified a small molecule capable of crossing the blood-brain barrier to prevent pathological protein aggregation in Parkinson’s disease, Lewy body dementia and multiple system atrophy.
-
NewsBlocking protein pathway may slow Huntington’s disease
Researchers have identified a previously unknown cellular mechanism involving tunnelling nanotubes and the protein SLC4A7 that enables toxic huntingtin to spread directly between neurons, offering new therapeutic targets for Huntington’s disease.
-
NewsProbiotic bacteria successfully attacks tumours in preclinical models
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
-
NewsLab-made lncRNA could lead to new anti-inflammatory drugs
Scientists at the University of Toronto have created long noncoding RNA outside living cells for the first time, a breakthrough that has already produced experimental anti-inflammatory molecules.